Printer Friendly


 PORTLAND, Ore., Dec. 19 /PRNewswire/ -- Richard B. Hollis, a

senior medical manufacturing executive with 18 years of sales and marketing management and corporate officer experience, has been named executive vice president of marketing and sales for Bioject Inc. (NASDAQ: BJCTF).
 Hollis, who will assume his responsibilities at Bioject on Dec. 23, was most recently vice president of marketing and sales, and corporate officer at Portland-based Instromedix, a manufacturer of medical devices for transtelephonic cardiac monitoring. His experience in the pharmaceutical and drug delivery industries includes the development and launch of several highly successful products and devices.
 For Genentech, Hollis planned and launched Activase (t-PA) with first year sales of the product exceeding $250 million. Hollis managed the development and launch of intravenous pump systems for IMED Corp., a startup company based in San Diego. During his nine years with IMED he was rapidly promoted from sales to general management positions until the company was sold to Warner Lambert for $468 million in 1984.
 "At Bioject, Mr. Hollis will initially focus on the rapid implementation of the company's current marketing plan, joining the efforts of our marketing and sales team," commented Carl Wilcox, president and CEO. "Hollis will also take an active role in strategic planning and operations necessary to meet the high rate of projected growth during the upcoming reporting periods."
 In his career, Hollis has implemented corporate strategic plans and driven sales of both small start-up and established companies. In the 1970s, Hollis worked for the parenteral division of Baxter Travenol, selling drug delivery products and nearly doubling product sales in his district.
 Bioject Inc. manufactures and markets the Biojector, a drug delivery system that is able to inject medication through the skin without a needle. It is currently used by private practice physicians and clinics along the U.S. west coast and in Texas.
 -0- 12/19/91
 /CONTACT: Dan Zenka or Tim Justice, both of Bioject, 503-639-7221/
 (BJCTF) CO: Bioject ST: Oregon IN: MTC SU: PER

RM -- SE003 -- 3935 12/19/91 13:14 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 19, 1991

Related Articles
Bioject Announces Cancellation of Contract With Schering AG
Bioject Announces New Directors
Bioject Announces Receipt of Second Payment from Merck & Co.
Bioject Receives FDA Market Clearance for First Needle-Free Device to Deliver Serono's Saizen(R) Human Growth Hormone for US Pediatric Market.
Bioject and Alkermes Sign License and Development Agreement.
Bioject Signs Additional Agreement With Amgen for Needle-Free Injection Systems; Product Licensing, Development and Supply Agreement Signed.
Bioject Announces Agreement Regarding Elan Stock; Bioject to Withdraw Lawsuit.
Bioject Announces That Amgen Elects Not to Pursue Development And Commercialization Under Licensing Agreements; Amgen Retains Options to Other...
Bioject Signs Agreement With Vical.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters